Following non-submission
AWMSG advice |
||
Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ceftobiprole (Zevtera®) cannot be endorsed for use within NHS Wales for the treatment of the following infections in adults: hospital-acquired pneumonia, excluding ventilator-associated pneumonia; and community-acquired pneumonia. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
||
|
||
Medicine details |
||
Medicine name | ceftobiprole (Zevtera®) | |
Formulation | 500 mg powder for concentrate for solution for infusion | |
Reference number | 1641 | |
Indication | Treatment of the following infections in adults: hospital-acquired pneumonia, excluding ventilator-associated pneumonia; and community-acquired pneumonia. Consideration should be given to official guidance on the appropriate use of antibacterial agents |
|
Company | Basilea Pharmaceuticals Ltd | |
BNF chapter | Infections | |
Assessment type | Non-submission | |
Status | Not endorsed (Statement of Advice) | |
Date of issue | 07/05/2014 |